Literature DB >> 31228621

Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018.

Haval Balata1, Kwun M Fong2, Lizza E Hendriks3, Stephen Lam4, Jamie S Ostroff5, Nir Peled6, Ning Wu7, Charu Aggarwal8.   

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide. Tobacco consumption remains the most important risk factor. Although the prevalence of smoking has decreased overall, it continues to be a significant burden for global health. It is estimated that there are still nearly 1 billion cigarette smokers worldwide. Prevention strategies have largely focused on tobacco control and prevention. However, we have witnessed a dramatic increase in the use of e-cigarettes and other vaping products. Primary chemoprevention has historically not been a successful strategy for lung cancer; however, focused approaches in specific groups of patients at high risk for development of lung cancer are underway. The majority of cases with NSCLC are diagnosed with locally advanced or metastatic disease, where the overall prognosis remains very poor. Early-stage NSCLC on the other hand has a much better prognosis and can usually be treated radically with either surgical resection or radical radiotherapy, with relatively favorable long-term outcomes. In addition to image-based screening, other methods such as breath-based and biofluid-based approaches are now being investigated for early detection of NSCLC. This review will focus on recent advancements in the field of prevention, screening, and early detection of NSCLC.
Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Early detection; Prevention; Screening

Mesh:

Year:  2019        PMID: 31228621     DOI: 10.1016/j.jtho.2019.06.011

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   20.121


  32 in total

1.  Clinical evaluation of contrast-enhanced CT combined with PET/CT in diagnosis of mediastinal lymph node metastasis of non-small-cell lung cancer.

Authors:  Xiaodong Li; Xiaomeng Zheng; Tianle Zhang; Xi Dong; Jian Su
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

2.  LncRNA TTN-AS1 Promotes Progression of Non-Small Cell Lung Cancer via Regulating miR-491-5p/ZNF503 Axis.

Authors:  Guanbin Qi; Lei Li
Journal:  Onco Targets Ther       Date:  2020-07-01       Impact factor: 4.147

3.  Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer.

Authors:  Ling Wang; Yue Dai; Fuliang Zhu; Zhimin Qiu; Yaqi Wang; Yinghui Hu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  Hsa_circ_0060937 accelerates non-small cell lung cancer progression via modulating miR-195-5p/HMGB3 pathway.

Authors:  Junfeng Xi; Yunfeng Xi; Zhibin Zhang; Yanhong Hao; Fei Wu; Burong Bian; Guangjun Hao; Weiwei Li; Shuqun Zhang
Journal:  Cell Cycle       Date:  2021-09-01       Impact factor: 5.173

5.  miR-489-3p promotes malignant progression of non-small cell lung cancer through the inactivation of Wnt/β-catenin signaling pathway via regulating USP48.

Authors:  Pei Zhang; Li Li; Bing Wang; Xu Ran; Shengrong Yang; Yujie Luo; Yunhe Li; Zhenghong Wang; Yi Liu; Bing Zhu
Journal:  Respir Res       Date:  2022-04-12

6.  Tumor-Derived Exosomal eIF4E as a Biomarker for Survival Prediction in Patients with Non-Small Cell Lung Cancer.

Authors:  Qian Dong; Liangliang Dong; Sheng Liu; Yan Kong; Mi Zhang; Xingwen Wang
Journal:  Med Sci Monit       Date:  2020-06-05

7.  Different Proteins Regulated Apoptosis, Proliferation and Metastasis of Lung Adenocarcinoma After Radiotherapy at Different Time.

Authors:  P L Dai; X S Du; Y Hou; L Li; Y X Xia; L Wang; H X Chen; L Chang; W H Li
Journal:  Cancer Manag Res       Date:  2020-04-02       Impact factor: 3.989

8.  Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.

Authors:  Myvizhi Esai Selvan; Marjorie G Zauderer; Charles M Rudin; Siân Jones; Semanti Mukherjee; Kenneth Offit; Kenan Onel; Gad Rennert; Victor E Velculescu; Steven M Lipkin; Robert J Klein; Zeynep H Gümüş
Journal:  J Thorac Oncol       Date:  2020-08-28       Impact factor: 15.609

9.  TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway.

Authors:  Xilin Zhang; Ying He; Yan Jiang; Ying Bao; Qiuqiang Chen; Dong Xie; Huanming Yu; Xiang Wang
Journal:  Oncol Rep       Date:  2021-06-29       Impact factor: 3.906

10.  Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.

Authors:  Yu-Jie Cui; Jia Liu; Miao-Miao Liu; Hong-Zhen Zhang
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.